Is Testosterone Therapy Safe for Men with Localized Prostate Cancer? A Review of Studies

What is it about?

The study investigates the oncological safety of testosterone replacement therapy (TRT) in hypogonadal patients with prostate cancer, noting the increased prevalence of testosterone deficiency (TD) with age and its treatment-related nature in prostate cancer. A systematic review analyzed 19 studies from a pool of 4067, spanning active surveillance, post-radical prostatectomy, and post-radiotherapy contexts. Findings indicate low progression and recurrence rates in TRT-exposed cohorts, though certainty is limited due to the lack of long-term, controlled data. Cautious TRT use is supported for low-to-intermediate-risk prostate cancer with diligent patient selection and monitoring until further randomized controlled trial data are available. The study highlights the need for more robust research to conclusively determine the safety of TRT in these patients.

Featured Image

Why is it important?

This research is crucial as it addresses the oncological safety of testosterone replacement therapy (TRT) in patients with hypogonadism and prostate cancer, a topic of considerable clinical relevance given the historical contraindications due to concerns of cancer progression. As testosterone deficiency can significantly impact the quality of life in aging men and those undergoing prostate cancer treatment, understanding the safety profile of TRT is vital for developing patient-centered treatment strategies. The study contributes to the ongoing debate by highlighting the need for careful patient selection and monitoring, thereby potentially broadening therapeutic options for managing testosterone deficiency in this patient population. Key Takeaways: 1. Oncological Safety: The research indicates that TRT does not significantly increase progression or recurrence rates in low-to-intermediate risk prostate cancer patients, suggesting that TRT could be cautiously considered in certain cases without exacerbating cancer outcomes. 2. Evidence Limitations: The findings are limited by the lack of long-term, prospective controlled studies, emphasizing the need for further research to ascertain the definitive safety and survival impact of TRT in prostate cancer patients. 3. Patient Selection and Monitoring: The study underscores the importance of diligent patient selection and monitoring when considering TRT for prostate cancer patients, advocating for its use only in cases of functionally significant hypogonadism where the benefits outweigh potential risks.